Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir versus oral ganciclovir prophylaxis for prevention of CMV disease after orthotopic liver transplant
2007-004729-16Phase 3Terminated
- Sponsor
- ViroPharma Incorporated
- Start
- Nov 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing Maribavir prophylaxis with Oral ganciclovir prophylaxis (2 arms). Primary endpoints: Incidence of CMV disease within 6 months post-transplant, Incidence of CMV disease within 100 days post-transplant and 1 more. Started Nov 2007; status: terminated.
02
Drugs
maribavirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2007-004729-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004729-16.